1. Home
  2. ONMD vs NRBO Comparison

ONMD vs NRBO Comparison

Compare ONMD & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONMD
  • NRBO
  • Stock Information
  • Founded
  • ONMD 2006
  • NRBO N/A
  • Country
  • ONMD United States
  • NRBO United States
  • Employees
  • ONMD N/A
  • NRBO N/A
  • Industry
  • ONMD
  • NRBO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ONMD
  • NRBO Health Care
  • Exchange
  • ONMD Nasdaq
  • NRBO Nasdaq
  • Market Cap
  • ONMD 23.9M
  • NRBO 27.9M
  • IPO Year
  • ONMD N/A
  • NRBO N/A
  • Fundamental
  • Price
  • ONMD $0.84
  • NRBO $2.35
  • Analyst Decision
  • ONMD
  • NRBO Strong Buy
  • Analyst Count
  • ONMD 0
  • NRBO 1
  • Target Price
  • ONMD N/A
  • NRBO $10.00
  • AVG Volume (30 Days)
  • ONMD 498.5K
  • NRBO 36.9K
  • Earning Date
  • ONMD 12-03-2024
  • NRBO 11-07-2024
  • Dividend Yield
  • ONMD N/A
  • NRBO N/A
  • EPS Growth
  • ONMD N/A
  • NRBO N/A
  • EPS
  • ONMD N/A
  • NRBO N/A
  • Revenue
  • ONMD $1,021,651.00
  • NRBO N/A
  • Revenue This Year
  • ONMD N/A
  • NRBO N/A
  • Revenue Next Year
  • ONMD N/A
  • NRBO N/A
  • P/E Ratio
  • ONMD N/A
  • NRBO N/A
  • Revenue Growth
  • ONMD N/A
  • NRBO N/A
  • 52 Week Low
  • ONMD $0.42
  • NRBO $2.08
  • 52 Week High
  • ONMD $4.43
  • NRBO $6.75
  • Technical
  • Relative Strength Index (RSI)
  • ONMD 52.31
  • NRBO 39.45
  • Support Level
  • ONMD $0.81
  • NRBO $2.30
  • Resistance Level
  • ONMD $0.87
  • NRBO $2.50
  • Average True Range (ATR)
  • ONMD 0.13
  • NRBO 0.26
  • MACD
  • ONMD -0.00
  • NRBO -0.01
  • Stochastic Oscillator
  • ONMD 53.27
  • NRBO 21.04

About ONMD OneMedNet Corp

OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.

About NRBO NeuroBo Pharmaceuticals Inc.

NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Share on Social Networks: